コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 urvival compared with those patients without carcinoid syndrome.
2 diagnosed with NETs, of whom 1786 (19%) had carcinoid syndrome.
3 cause distinct clinical syndromes, including carcinoid syndrome.
4 , becoming much more common in patients with carcinoid syndrome.
5 nd pulmonary insufficiency) in patients with carcinoid syndrome.
6 All patients with MCH had carcinoid syndrome.
7 Cardiac metastases are uncommon in carcinoid syndrome.
8 egral part of the echo exam in patients with carcinoid syndrome.
9 more often with flushing, diarrhea, and the carcinoid syndrome.
10 ical presentation, except in the case of the carcinoid syndrome.
11 ted levels of 5-HIAA without any evidence of carcinoid syndrome.
12 number of metastatic sites, and presence of carcinoid syndrome.
13 wel movement (BM) frequency in patients with carcinoid syndrome.
14 ars [95% CI 4.5-5.4]) than did those without carcinoid syndrome (5.6 years [5.4-5.9]; hazard ratio 1.
15 se is a frequent occurrence in patients with carcinoid syndrome and is responsible for substantial mo
17 l serotonin is associated with symptoms like carcinoid syndrome and pulmonary arterial hypertension.
20 [5-hydroxytryptamine (5-HT)] levels, such as carcinoid syndrome, and the use of serotonin agonists, s
21 cells causes severe symptoms typical for the carcinoid syndrome, and tryptophan hydroxylase inhibitor
24 ved, octreotide LAR controls the symptoms of carcinoid syndrome at least as well as SC octreotide.
25 es the diarrhea and flushing associated with carcinoid syndrome but requires long-term multiple injec
26 noid valvular heart disease in patients with carcinoid syndrome by serial echocardiography, correlati
30 7 patients with documented liver metastases, carcinoid syndrome developed in only 13 patients (48%),
31 insurance claims of flushing, diarrhoea, or carcinoid syndrome during the 3 months before and after
37 sed the proportion of patients with NETs and carcinoid syndrome in the USA and associated clinical fa
38 an-Armitage trend test to identify trends in carcinoid syndrome incidence and Cox regression to asses
40 rong recommendation was made for symptomatic carcinoid syndrome informing treatment in midgut neuroen
41 This population-based analysis reveals that carcinoid syndrome is significantly associated with tumo
43 tients with MEN, particularly those with the carcinoid syndrome or pheochromocytoma, to undergo surge
44 cant difference in the reported incidence of carcinoid syndrome (p<0.0001), as was tumour grade, stag
45 was used more frequently in patients without carcinoid syndrome (p=0.009); use of radiotherapy was no
46 ch develops in the majority of patients with carcinoid syndrome, presents the anesthesiologist with m
47 ctive study, we identified 200 patients with carcinoid syndrome referred for echocardiography in whom
48 (p=0.003) were more common in patients with carcinoid syndrome than in those without it, whereas sur
50 mes such as xanthomas, acanthosis nigricans, carcinoid syndrome, unusual erythematous eruptions such
53 Our sample included 71 patients with the carcinoid syndrome who underwent serial echocardiographi
55 oactive amines into the bloodstream, causing carcinoid syndrome, with symptoms including flushing and